Dual-Amplification Strategy with Copper Nanoclusters Enables Highly Sensitive Endometriosis Diagnosis

ACS Publications, Analytical Chemistry Taiwan

Overview

National Taiwan University researchers have developed a fluorescent biosensing platform for highly sensitive and specific detection of endometriosis biomarker miR-199a-5p in serum. The platform integrates copper nanoclusters (CuNCs) with a dual isothermal amplification strategy (EDC) and magnetic beads for enhanced detection efficiency. It promises a rapid, low-cost, and label-free diagnostic tool with exceptional specificity, capable of distinguishing single-base mismatches.

In Depth

Endometriosis Diagnostic Challenges and the Importance of Biomarker Research

Endometriosis is a chronic inflammatory disease affecting many women, with diagnosis often taking years, leading to significant physical and psychological burden. Current diagnostic methods are frequently invasive, driving a strong demand for non-invasive, highly sensitive early diagnostic tools. Technologies for accurately detecting trace microRNAs (miRNAs) and other biomarkers in blood are crucial for early intervention.

Integration of Copper Nanoclusters and Dual Amplification Strategy

The research team at National Taiwan University developed an innovative fluorescent biosensing platform for detecting miR-199a-5p, an endometriosis biomarker, in serum samples. The core of this technology lies in two key components:

• Utilization of Copper Nanoclusters (CuNCs): CuNCs possess intrinsic fluorescent properties and can alter their fluorescence intensity upon binding to specific nucleic acid sequences. This allows them to function as optical probes for detecting target molecules.
• Integration of a Dual Isothermal Amplification Strategy (Entropy-driven circuit, EDC): This strategy enables efficient amplification of the detection signal even when the target miRNA is present in very small quantities. The use of magnetic beads further enhances the efficiency of the amplification reaction by enabling effective separation of target miRNA from complex serum samples.

This platform has demonstrated exceptionally high specificity, capable of distinguishing single-base mismatches, and maintains robust performance even in complex biological samples.

Clinical Applications and Future Outlook

This new diagnostic platform holds significant promise for the early diagnosis of endometriosis and monitoring of treatment efficacy. Its characteristics of rapidity, low cost, and label-free operation make it suitable for Point-of-Care Testing (POCT) devices, leading to more accessible and less burdensome diagnostic tools for patients. Early diagnosis can delay disease progression, alleviate pain, and reduce the risk of complications such as infertility. Future challenges include extensive clinical validation to further solidify its efficacy and aiming for widespread adoption as a practical POCT device.